BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15923428)

  • 1. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
    Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
    Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
    Bazan V; Agnese V; Corsale S; Calò V; Valerio MR; Latteri MA; Vieni S; Grassi N; Cicero G; Dardanoni G; Tomasino RM; Colucci G; Gebbia N; Russo A;
    Ann Oncol; 2005 May; 16 Suppl 4():iv50-55. PubMed ID: 15923430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
    Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
    J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutations in colorectal cancer from Tunisia: relationships with site of tumor origin, microsatellite instability and KRAS mutations.
    Aissi S; Buisine MP; Zerimech F; Kourda N; Moussa A; Manai M; Porchet N
    Mol Biol Rep; 2014 Mar; 41(3):1807-13. PubMed ID: 24443225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients.
    Chang YS; Chang SJ; Yeh KT; Lin TH; Chang JG
    Onkologie; 2013; 36(12):719-24. PubMed ID: 24356563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of TP53 and RAS mutations on cerebellar glioblastomas.
    Milinkovic VP; Skender Gazibara MK; Manojlovic Gacic EM; Gazibara TM; Tanic NT
    Exp Mol Pathol; 2014 Oct; 97(2):202-7. PubMed ID: 25036404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study.
    Andreyev HJ; Norman AR; Cunningham D; Oates J; Dix BR; Iacopetta BJ; Young J; Walsh T; Ward R; Hawkins N; Beranek M; Jandik P; Benamouzig R; Jullian E; Laurent-Puig P; Olschwang S; Muller O; Hoffmann I; Rabes HM; Zietz C; Troungos C; Valavanis C; Yuen ST; Ho JW; Croke CT; O'Donoghue DP; Giaretti W; Rapallo A; Russo A; Bazan V; Tanaka M; Omura K; Azuma T; Ohkusa T; Fujimori T; Ono Y; Pauly M; Faber C; Glaesener R; de Goeij AF; Arends JW; Andersen SN; Lövig T; Breivik J; Gaudernack G; Clausen OP; De Angelis PD; Meling GI; Rognum TO; Smith R; Goh HS; Font A; Rosell R; Sun XF; Zhang H; Benhattar J; Losi L; Lee JQ; Wang ST; Clarke PA; Bell S; Quirke P; Bubb VJ; Piris J; Cruickshank NR; Morton D; Fox JC; Al-Mulla F; Lees N; Hall CN; Snary D; Wilkinson K; Dillon D; Costa J; Pricolo VE; Finkelstein SD; Thebo JS; Senagore AJ; Halter SA; Wadler S; Malik S; Krtolica K; Urosevic N
    Br J Cancer; 2001 Sep; 85(5):692-6. PubMed ID: 11531254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.
    Andreyev HJ; Norman AR; Cunningham D; Oates JR; Clarke PA
    J Natl Cancer Inst; 1998 May; 90(9):675-84. PubMed ID: 9586664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.
    Rao B; Gao Y; Huang J; Gao X; Fu X; Huang M; Yao J; Wang J; Li W; Zhang J; Liu H; Wang L; Wang J
    Int J Colorectal Dis; 2011 May; 26(5):593-601. PubMed ID: 21404058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.
    Ines C; Donia O; Rahma B; Ben Ammar A; Sameh A; Khalfallah T; Abdelmajid BH; Sabeh M; Saadia B
    Tumour Biol; 2014 Jul; 35(7):7163-75. PubMed ID: 24763823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.
    Malhotra P; Anwar M; Nanda N; Kochhar R; Wig JD; Vaiphei K; Mahmood S
    Tumour Biol; 2013 Jun; 34(3):1901-11. PubMed ID: 23526092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
    Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
    Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
    Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
    J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
    Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M
    Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer.
    Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Verlind E; Hermans J; Poppema S; Buys CH; Plukker JT
    Dis Colon Rectum; 2001 Mar; 44(3):358-63. PubMed ID: 11289281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.
    Iacopetta B; Russo A; Bazan V; Dardanoni G; Gebbia N; Soussi T; Kerr D; Elsaleh H; Soong R; Kandioler D; Janschek E; Kappel S; Lung M; Leung CS; Ko JM; Yuen S; Ho J; Leung SY; Crapez E; Duffour J; Ychou M; Leahy DT; O'Donoghue DP; Agnese V; Cascio S; Di Fede G; Chieco-Bianchi L; Bertorelle R; Belluco C; Giaretti W; Castagnola P; Ricevuto E; Ficorella C; Bosari S; Arizzi CD; Miyaki M; Onda M; Kampman E; Diergaarde B; Royds J; Lothe RA; Diep CB; Meling GI; Ostrowski J; Trzeciak L; Guzinska-Ustymowicz K; Zalewski B; Capellá GM; Moreno V; Peinado MA; Lönnroth C; Lundholm K; Sun XF; Jansson A; Bouzourene H; Hsieh LL; Tang R; Smith DR; Allen-Mersh TG; Khan ZA; Shorthouse AJ; Silverman ML; Kato S; Ishioka C;
    Ann Oncol; 2006 May; 17(5):842-7. PubMed ID: 16524972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.